If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 71 - 80 of 294
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Protocol No
ALLIANCE-A012103
Categories
A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Protocol No
NRG-BR008-HERO
Categories
FLIP Device - Feasibility Study for Quantifying Fatty Liver Using Thermoacoustic Imaging
Assessment of Fatty Liver With Thermo-acoustic Device
Protocol No
GI-ENDRA-FLIP-DEVICE
Categories
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC
S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Protocol No
SWOG-S1803-CTN-1706-DRAMMATIC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment with Standard of Care Therapy with an Immu
This trial is being run to find out how well the trial drug GEN1046 acts against NSCLC and if it is safe both as single treatment and in combination with Pembrolizumab to treat your NSCLC.
Protocol No
GENMAB-GCT1046-04
Categories
A Randomized, Open-Label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in Comparison with Atezolizumab Plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A randomized study to compare Atezolizumab plus Chemotherapy vs HLX10 plus Chemo in ES-SCLC
Protocol No
SHB-HLX10-005-SCLC301-E
Categories
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Protocol No
INF-AN2-EBO-301-MAC
Categories
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due t
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (diSArm)
Protocol No
INF-ARMATA-DISARM
Categories
Expanded Access IND Protocol: Use of Tecovirimat (TPOXX) for Treatment of Human Orthopoxvirus Infections (CDC IND 116039, CDC IRB Protocol #6402)
TPOXX for Treatment of Human Orthopoxvirus Infections
Protocol No
INF-CDC-TPOXX-EA-IND-MONKEYPOX
Categories
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)
Protocol No
NEPH-ALEXION-ALXN1210-202
Categories